ADMA Biologics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for ADMA Biologics, Inc. (ADMA) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income197.67-28.24-65.90-71.65-75.75-48.28-65.74
Depreciation & Amortization8.058.337.117.255.584.303.45
Deferred Income Tax-84.280.000.000.000.000.000.00
Stock Based Compensation13.626.195.223.492.860.000.00
Change in Working Capital-18.54-10.12-18.29-49.91-33.58-33.50-3.69
Change in Accounts Receivable-22.58-11.9213.07-15.34-9.770.000.00
Change in Inventory2.67-9.63-38.56-43.19-28.470.000.00
Change in Accounts Payable4.153.840.801.361.900.000.00
Change in Other Working Capital-2.786.296.401.752.560.000.00
Other Operating Activities-83.186.299.531.712.66-11.640.96
Net Cash from Operating Activities118.678.80-59.51-112.37-102.00-78.95-62.68
Investing Activities
Capital Expenditures-8.23-4.98-13.9113.5112.733.81-2.10
Sales/Maturities of Investments-0.35-0.210.000.00-0.03-0.030.00
Other Investing Activities-0.350.000.000.00-0.03-0.030.00
Net Cash from Investing Activities-8.58-4.98-13.91-13.51-12.72-3.84-2.10
Financing Activities
Debt Repayment-60.00-158.60-100.04-0.03-13.98-30.00-0.04
Common Stock Issued7.491.1064.82121.14131.2048.4042.94
Common Stock Repurchased-4.97-1.42-2.90-0.060.000.000.00
Other Financing Activities-0.83-16.49-4.78-0.0625.9220.250.00
Net Cash from Financing Activities-58.30-38.99108.85121.05170.65109.5542.92
Summary
Net Change in Cash51.80-35.1735.43-4.8355.9226.75-21.85
Cash at Beginning of Period51.3586.5251.0955.9226.7526.7548.61
Cash at End of Period103.1551.3586.5251.0982.6753.5126.75
Free Cash Flow110.453.82-73.42-125.88-114.73-82.77-64.77
Supplemental Disclosures
Interest Paid10.6718.0513.8811.1610.270.000.00
Income Taxes Paid9.390.000.000.000.000.000.00